SCHEMBL16235471

SCHEMBL16235471

O=C(O)c1cccc(S(=O)(=O)Nc2cncc(Cl)c2O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.65
▸ TSHR P16473 1/20 0.65
▸ PTK2B Q14289 1/20 0.65
▸ KMT2A Q03164 4/20 0.54
▸ MAPT P10636 1/20 0.51
▸ MEN1 O00255 2/20 0.49
▸ CCR2 P41597 1/20 0.48
▸ AKR1C3 P42330 1/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ ACLY P53396 1/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CASP3 P42574 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235652 0.87 SLC40A1 (0.55) KDM4ETSHRPTK2BKMT2AMEN1
SCHEMBL16235275 0.83 HSD11B1 (0.47) KDM4ETSHRPTK2BRAB9APKM
SCHEMBL7373672 0.79 KDM4E (1.00) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL28053418 0.78 SLC40A1 (0.56) KMT2AMEN1ALDH1A1GAAHPGD
SCHEMBL16235193 0.76 S100A9 (0.48) ACLY
SCHEMBL16235055 0.76 ALDH1A1 (0.47) TSHRKMT2AMAPTMEN1CCR2
SCHEMBL7374106 0.75 KDM4E (0.72) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL28053260 0.75 ACLY (0.51) KMT2AMEN1CCR2ACLYALDH1A1
SCHEMBL16020335 0.75 KDM4E (0.60) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL16020314 0.73 KDM4E (0.55) KDM4ETSHRPTK2BKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
CN-105377837-A N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB 2016-03-02 — — CN disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 KDM4E 3512/4885TSHR 3875/4885PTK2B 1059/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 KDM4E 3512/4885TSHR 3875/4885PTK2B 1059/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B KDM4E 3670/4885TSHR 4024/4885PTK2B 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback